BTKi Resistance in CLL

CME

A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: October 01, 2024

Expiration: March 31, 2025

Matthew S Davids
Matthew S Davids, MD, MMSc
Lindsey Roeker
Lindsey Roeker, MD

Activity

Progress
1 2
Course Completed

References

  1. National Comprehensive Cancer Network. NCCN guidelines: Chronic lymphocytic leukemia (CLL). Version 3.2024. nccn.org. Accessed October 24, 2024.
  2. Stephens DM, Byrd JC. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. Blood. 2021;138:1099-1109.
  3. Davids MS, Mato AR, Hum J, et al. MAJIC: A phase 3 prospective, multicenter, randomized, open-label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Blood. 2021;138(Suppl 1):1553.
  4. Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia. Leukemia. 2022;36:1171-1175.
  5. Al-Sawaf O, Zhang C, Lu T, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: Extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39:4049-4060.
  6. Thompson MC, Harrup RA, Coombs CC, et al. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv. 2022;6:4553-4557.
  7. Ghia P, Wierda W, Barr P, et al. Relapse after first-line fixed duration ibrutinib + venetoclax: high response rates to ibrutinib retreatment and absence of BTK mutations in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with up to 5 years of follow-up in the phase 2 Captivate study. Presented at: American Society of Hematology Annual Meeting; December 9-12, 2023. Abstract 633.
  8. Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74:1667-1678.
  9. Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319-332.
  10. Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441-3452.
  11. Allen JN, Kittai AS, James D, et al. A matching-adjusted indirect comparison of acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naïve chronic lymphocytic leukemia. Blood. 2023;142(Suppl 1):6563.
  12. Kittai AS, Skarbnik A, Miranda M, et al. A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia. Am J Hematol. 2023;98:E387-E390.
  13. Burger J, Kim E, Lopez W, et al. A phase II study of time-limited treatment with acalabrutinib plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia. Presented at: 2024 European Hematology Association Congress; June 13-16, 2024. Abstract P1841.
  14. Nakhoda S, Vistarop A, Wang YL. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2023;200:137-149.
  15. Sedlarikova L, Petrackova A, Papajik T, et al. Resistance-associated mutations in chronic lymphocytic leukemia patients treated with novel agents. Front Oncol. 2020;10:894.
  16. Bodor C, Kotmayer L, Laszlo T, et al. Screening and monitoring of the BTK(C481S) mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy. Br J Haematol. 2021;194:355-364.
  17. Nawaratne V, Sondhi AK, Abdel-Wahab O, et al. New means and challenges in the targeting of BTK. Clin Cancer Res. 2024;30:2333-2341.
  18. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107-1120.
  19. Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;38:4042-4054.
  20. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225-2236.
  21. Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65-75.
  22. Naeem A, Utro F, Wang Q, et al. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv. 2023;7:1929-1943.
  23. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397:892-901.
  24. Wang E, Mi X, Thompson MC, et al. Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors. N Engl J Med. 2022;386:735-743.
  25. Woyach JA, Jones D, Jurczak W, et al. Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib. Blood. 2024;[Epub ahead of print].
  26. Blombery P, Thompson ER, Lew TE, et al. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blood Adv. 2022;6:5589-5592.
  27. Tam C, Thompson PA. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Adv. 2024;8:2300-2309.
  28. Linton K, Collins G, Forconi F, et al. Latest results from an ongoing first-in-human phase 1A/B study of NX-5948, a selective Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory CLL and other B-cell malignancies. June 13-16, 2024. Abstract S155.
  29. Vazquez R, Breal C, Zalmai L, et al. Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis. Blood Cancer J. 2021;11:62.
  30. Wong RL, Choi MY, Wang HY, et al. Mutation in Bruton tyrosine kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia. Leukemia. 2024;38:1818-1821.
  31. Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023;402:641-654.